Sign In
Buy NLSP
$0.762
+0 (+0%)
At Close: Mar 11, 2026
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
05:00pm, Friday, 19'th Apr 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
04:30pm, Friday, 22'nd Mar 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discov
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
01:40pm, Wednesday, 20'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
07:30am, Wednesday, 20'th Mar 2024
The exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacolo
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
08:00am, Thursday, 14'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing Compliance
07:00am, Monday, 11'th Mar 2024
ZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discove
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
07:30am, Friday, 23'rd Feb 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the dis
Notice of Deficiency with Nasdaq Continued Listing Requirements
04:30pm, Friday, 12'th Jan 2024
ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the disco
NLS Pharmaceutics CEO Issues Letter to Shareholders
04:30pm, Friday, 29'th Dec 2023
ZURICH, SWITZERLAND / ACCESSWIRE / December 29, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company, focused on the discovery
Why Is NLS Pharmaceutics (NLSP) Stock Down 24% Today?
09:06am, Monday, 04'th Dec 2023
NLS Pharmaceutics (NASDAQ: NLSP ) stock is taking a beating on Monday as the company's shares come down from a rally on Friday. The news that sent shares of NLSP stock higher on Friday concerned an e
The option agreement grants NLS Pharmaceutics Ltd. the exclusive option to in-license all of Aexon Labs' assets for the potential treatment of narcolepsy and other neuro-degenerative disorders, and al
NLS Pharmaceutics Announces Election of Additional Board Members
07:30am, Tuesday, 28'th Nov 2023
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University of Bern, focused on sleep disorders Professor Flor
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
08:30am, Monday, 27'th Nov 2023
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery a
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
08:00am, Thursday, 16'th Nov 2023
NLS has executed a non-binding term sheet for licensing of NLS intellectual property NLS has secured an additional bridge loan through insiders to extend cash runway NLS has implemented significant in
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
04:30pm, Wednesday, 25'th Oct 2023
ZURICH, SWITZERLAND / ACCESSWIRE / October 25, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP,NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and
